Seeking Alpha

More on Regeneron (REGN) Q4: shares +8.9% after the company raises its 2012 U.S. sales forecast...

More on Regeneron (REGN) Q4: shares +8.9% after the company raises its 2012 U.S. sales forecast for its key Eylea eye drug to $250M-$300M from an earlier prediction of $140M-$160M. Regeneron also discloses incidents of inflammation following the use of Eylea, although the overall rate of adverse events was ~0.01%.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector